Enteral administration of sorbent polymer for treatment and prophylaxis of inflammation

Patent metadata

Field	Value
Publication number	US-9603807-B2
Application number	US-201314025322-A
Country	US
Kind code	B2
Filing date	Sep 12, 2013
Priority date	Oct 2, 2008
Publication date	Mar 28, 2017
Grant date	Mar 28, 2017

Abstract

The invention provides a method of ameliorating inflammation in a patient involving administering to the patient a therapeutically effective dose of composition including polystyrene divinyl benzene copolymer and a polyvinyl pyrrolidone polymer. More particularly, the method relates to using these polymers as an enteral sorbent preparation to remove inflammatory mediators, such as cytokines, from the intestinal lumen. The polymers can be in the form of a preparation of polystyrene divinyl benzene copolymer beads with a biocompatible polyvinyl pyrrolidone polymer coating.

First claim

What is claimed is:

1. A method of ameliorating inflammation in a patient suffering from or at risk of inflammation comprising:
administering to the patient a therapeutically effective dose of a composition comprising a sorbent, wherein the sorbent comprises both polystyrene divinyl benzene copolymer and polyvinyl pyrrolidone polymer,
wherein the administration results in enteral adsorption of an inflammatory mediator.

2. The method of claim 1 , wherein an inflammatory mediator is associated with sepsis, surgery, cytotoxic chemotherapy, bone marrow manipulation, major tissue injury, mesenteric hypoperfusion, gut-mucosal injury, malaria, local gastrointestinal inflammatory disease, acute lung inflammation, pancreatitis, rheumatoid arthritis, or collagen vascular diseases.

3. The method of claim 1 , wherein the administration is oral or rectal.

4. The method of claim 1 , wherein the administration is via feeding tube.

5. The method of claim 1 , wherein the patient is human.

6. The method of claim 1 , wherein the inflammation is systemic.

7. The method of claim 1 , wherein the inflammation is associated with local gastro-intestinal injury or disease.

8. The method of claim 1 , wherein the composition consists essentially of the sorbent.

9. The method of claim 1 , wherein the sorbent is in the form of beads.

10. The method of claim 9 , wherein the beads comprise polystyrene divinyl benzene copolymer with a polyvinyl pyrrolidone polymer coating.

11. The method of claim 9 , wherein the beads consist essentially of polystyrene divinyl benzene copolymer and polyvinyl pyrrolidone polymer.

12. The method of claim 9 , wherein the bead diameter is about 200 μm to about 800 μm.

13. The method of claim 9 , wherein the beads have pores on the surface of the beads.

14. The method of claim 13 , wherein the pores have a diameter of about 10 Å to about 100 Å.

15. The method of claim 13 , wherein the beads comprise a distribution of pore sizes.

16. The method of claim 13 , wherein the pores have a diameter of at least 10 Å.

17. The method of claim 9 , wherein the beads have an internal surface area of about 700 m 2 per gram to about 1000 m 2 per gram of beads.

18. The method of claim 9 , wherein the beads adsorb cytokines.

19. The method of claim 9 , wherein the beads adsorb one or more molecules selected from the group consisting of tumor necrosis factor (TNF), interleukin (IL)-6, IL-10, high mobility group protein B (HMGB)-1, IL-8, IL-18, monocyte chemotactic protein (MCP)-1, IL-2, IL-1β, and S100B.

20. The method of claim 9 , wherein composition is in the form of a pill comprising the beads and a pharmaceutically acceptable excipient.

21. The method of claim 9 , wherein the beads are administered in the form of a slurry, gel, or powder comprising the beads.

22. The method of claim 9 , wherein the beads have a diameter of at least 200 μm.

23. The method of claim 9 , wherein the beads have an internal surface area of at least 700 m 2 per gram of beads.

24. A method of treating a patient suffering from an inflammatory response comprising:
enterally administering to the patient a therapeutically effective dose of a composition consisting essentially of polystyrene divinyl benzene copolymer and a polyvinyl pyrrolidone polymer.

25. The method of claim 24 , wherein the composition consisting essentially of the polystyrene divinyl benzene copolymer and polyvinyl pyrrolidone polymer is in the form of beads.

26. The method of claim 25 , wherein the beads consist essentially of polystyrene divinyl benzene copolymer with a polyvinyl pyrrolidone polymer coating.

27. The method of claim 24 , wherein the composition is administered orally, rectally, or via a feeding tube.

28. The method of claim 24 , wherein the patient is human.

29. The method of claim 24 , wherein the inflammatory response is systemic.

30. The method of claim 24 , wherein the inflammatory response is associated with local gastro-intestinal injury or disease.

31. A method of reducing inflammation in a patient suffering from or at risk of same, comprising:
enterally administering to the patient a therapeutically effective dose of a composition comprising beads of a sorbent that adsorbs a mediator of inflammation, wherein the sorbent comprises both polystyrene divinyl benzene copolymer and polyvinyl pyrrolidone polymer.

32. The method of claim 31 , wherein the beads comprise polystyrene divinyl benzene copolymer with a polyvinyl pyrrolidone polymer coating.

33. The method of claim 31 , wherein the patient is human.

34. The method of claim 31 , wherein the inflammation is systemic.

35. The method of claim 31 , wherein the inflammation is associated with local gastro-intestinal injury or disease.

36. The method of claim 31 , wherein the composition consists essentially of the beads of a sorbent.

37. An orally-admissible pharmaceutical dosage form comprising, as active principal, beads comprising both polystyrene divinyl benzene copolymer and polyvinyl pyrrolidone polymer.

38. The dosage form of claim 37 , comprising one or more pharmaceutically acceptable excipients.

39. The dosage form of claim 37 , which is in the form of a capsule.

40. The dosage form of claim 37 , in the form of a pill, slurry, gel, or powder.

41. The dosage form of claim 37 , wherein the beads comprise polystyrene divinyl benzene copolymer coated with a polyvinyl pyrrolidone polymer.

42. The dosage form of claim 37 , wherein the beads consist essentially of polystyrene divinyl benzene copolymer and polyvinyl pyrrolidone polymer.

43. The dosage form of claim 37 , wherein the bead diameter is at least 200 μm.

44. The dosage form of claim 37 , wherein the beads have pores on the surface of the beads.

45. The dosage form of claim 44 , wherein said pores have a diameter of at least 10 Å.

46. The dosage form of claim 37 , wherein the beads comprise a distribution of pore sizes.

47. The dosage form of claim 37 , wherein the beads have an internal surface area of at least 700 m 2 per gram of beads.

Assignees

• Univ Of Pittsburgh—Of The Commonwealth System Of Higher Education

Inventors

• Kellum John A
• Fink Mitchell P

Classifications

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P33/06

  Antimalarials · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title